Aptevo Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| For the Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $(14,540) | $(14,378) |
| General and administrative | (11,772) | (10,224) |
| Loss from operations | (26,312) | (24,602) |
| Other income: | ||
| Other income, net | 345 | 472 |
| Net loss | $(25,967) | $(24,130) |
| Dividend attributable to down round feature of warrants | (1,571) | — |
| Net loss attributable to common stockholders | $(27,538) | $(24,130) |
| Basic and diluted net loss per share: | $(87.27) | $(31,460.23) |
| Shares used in calculation: | 315,535 | 767 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.